Big pharma companies are making greater efforts to improve access to medicines in the developing world, but corruption and intellectual property (IP) issues are areas of concern, says a new report.
The biannual Access To Medicines Index (ATMI) – which is funded by the Bill & Melinda Gates Foundation and the UK and Dutch governments – puts GlaxoSmithKline at the top of its rankings in 2014 for the fourth time, followed by Novo Nordisk and Johnson & Johnson.
{iframe}http://www.pmlive.com/pharma_news/gsk_tops_pharma_access_to_medicines_table_617189{/iframe}